|
Company Background:
Patanjali Ayurved Ltd. was founded in 2006 by Baba Ramdev and Acharya Balkrishna with the vision of promoting Ayurveda, yoga, and natural wellness. Initially, the company focused on manufacturing Ayurvedic medicines and personal care products, distributing them through a small network of stores. Baba Ramdev’s growing popularity as a yoga guru helped the brand gain recognition, while Acharya Balkrishna oversaw product formulation and business operations..
Company Growth:
Between 2017 and 2020, Patanjali diversified into dairy products, frozen foods, and apparel (Patanjali Paridhan). Patanjali Ayurved Ltd. pursued strategic acquisitions and internal restructuring to strengthen its position in the fast-moving consumer goods (FMCG) sector. In December 2019, the company acquired the bankrupt..
Ayurvedic Market in India:
The Ayurvedic market in India had evolved into a rapidly expanding and competitive segment of the wellness and healthcare industry, driven by a growing interest in natural and preventive health solutions and supported by government initiatives. It included a wide range of products such as herbal formulations, wellness supplements, personal care items, and therapeutic medicines derived from traditional principles.
The Coronil Controversy:
The Coronil Kit consisted of three elements. The first element was Coronil, an Ayurvedic tablet containing ashwagandha (Indian ginseng), giloy (heart leaved moonseed), and tulsi (Holy Basil), claimed to boost immunity and support respiratory health. Its second element Swasari Vati, was a herbal formulation used to relieve cough, congestion, and breathing difficulties by supporting lung function. The third element Anu Taila, was a medicated nasal oil meant to be applied in the nostrils to lubricate nasal passages and enhance respiratory immunity..
Way Forward:
Following the ban and legal scrutiny over claims that Coronil could “cure” COVID-19, Patanjali Ayurved Ltd faced major legal, and marketing challenges to its reputation. The company responded with public clarifications, emphasizing Coronil’s Ayurvedic foundation, regulatory approvals, and internal clinical trials to defend its credibility. It complied with Court directives by removing misleading advertisements and issuing formal apologies to the Supreme Court to resolve contempt proceedings. However, the controversy caused lasting damage to the company’s reputation, with critics labeling its marketing as aggressive and unethical. Hospitals, pharmacies, and export partners became cautious in collaborating with the company, limiting institutional and government distribution..
EXHIBITS:
Exhibit I: Public Apology Made by Patanjali Ayurved Ltd.
Exhibit II: Timeline of Series of Events of Coronil Kit
Exhibit III: Controversial Packaging of Coronil Kit
Exhibit IV:
Immunity Supplement Sales during COVID-19
Exhibit V:Post-Ban Packaging of Coronil Kit
|
|
